Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Profile Avatar - Palmy Investing

Wuhan Easy Diagnosis Biomedicine Co.,Ltd.

Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of in vitro diagnostic reagents and diagnostic equipment in China and internationally. Its products portfolio includes molecular diagnostic products, …

Medical - Devices
CN, Wuhan [HQ]
Financials

Analysts

Earnings
Reported
Past Estimate Consensus
Future Estimate Consensus
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. can't present any analysts estimates at the moment detail analysis.
Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Overall Consensus
Grading Consensus
Click to each, to see the grade
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. can't present the grade consensus distribution right now.
Price Target Consensus
Price Then
$n/a
Price Target
$n/a
Price Now
$18.47
End of 002932.SZ's Analysis
CIK: - CUSIP: - ISIN: CNE1000033Q7 LEI: - UEI: -
Secondary Listings
002932.SZ has no secondary listings inside our databases.